Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors

Journal of Nuclear Medicine

Volumn 45, Issue 3, 2004, Pages 357-365

  Antoch, Gerald ^a,b   Kanja, Jörg ^a   Bauer, Sebastian ^a   Kuehl, Hilmar ^a   Renzing Koehler, Katrin ^a   Schuette, Jochen ^a   Bockisch, Andreas ^a   Debatin, Jörg F ^a   Freudenberg, Lutz S ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Gastrointestinal stromal tumor; Imatinib; PET CT

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; HUMAN; INTERMETHOD COMPARISON; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; IMAGE SUBTRACTION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STROMA CELL; TREATMENT OUTCOME; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STROMAL CELLS; SUBTRACTION TECHNIQUE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 2342561799     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding their biology. Hum Pathol. 1999;30:1213-1220.
2. Plaat BE, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol. 2000;18:3211-3220.
3. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stroma tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054-5058.
4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
5. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421-1423.
6. Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec). Med Klin. 2002;97(suppl 1):28-30.
7. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
8. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol. 1999;154:53-60.
9. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999;59:4297-4300.
10. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
11. van den Abbeele AD, Badawi RD, Cliche JP, et al. Response to imatinib mesylate (Gleevec) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT [abstract]. Radiology. 2002;225(suppl):424.
12. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-2020.
13. Choi H, Faria SC, Benjamin RS, Podoloff DA, Macapinlac HA, Charnsangavej C. Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIST) with CT and PET: a quantitative analysis [abstract]. Radiology. 2002;225(suppl):583.
14. Chen MYM, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR. 2002;179:1059-1062.
15. Townsend DW. A combined PET/CT scanner: the choices. J Nucl Med. 2001;42:533-534.
16. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology. 2002;225:575-581.
17. Antoch G, Kaiser GM, Mueller AB, et al. Dual-modality PET/CT imaging in monitoring intra-operative radiation therapy of liver tissue in a pig model. Radiology. In press.
18. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-1379.
19. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002;38:S83-S87.
20. Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dualmodality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging. 2003;30:588-596.
21. Kinahan PE, Townsend DW, Beyer T, et al. Attenuation correction for a combined 3D PET/CT scanner. Med Phys. 1998;25:2046-2053.
22. 18F]-fluorodeoxyglucose and positron emisson tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999;35:1773-1782.
23. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. Offset Publication No. 48.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidlines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
25. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions. JAMA. 2001;285:914-924.
26. Janicek MJ, Potter A, Merriam P, Demetri GD. Does pattern of metastases and early measurable changes after treatment predict therapy effect in gastrointestinal stromal tumor (GIST) on STI571 (imatinib) [abstract]. Radiology. 2002;225(suppl):583.
27. Antoch G, Freudenberg LS, Egelhof T, et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med. 2002;43:1339-1342.